The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AG-H-01881     (5S,6R)-6-[(2R)-2-amino-2- carboxy...

Synonyms: CTK2H8110, 75715-89-8
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of leukotriene E4


High impact information on leukotriene E4

  • The increased levels of the biologically active, proinflammatory mediators LTE4 and LTB4 might be of pathophysiological significance in peroxisome deficiency disorders [5].
  • Urinary LTE4 excretion was significantly higher in patients with kwashiorkor than in controls (118.8 [SD 28.5] vs 31.1 [19.3] nmol/mol creatinine; p < 0.01) [2].
  • However, using laser-Doppler flowmetry, leukotrienes C4 and D4 were found, when administered intraarterially at doses in the 0.05-1.0 micrograms/kg per min range, to produce dose-dependent reductions of gastric blood flow while N-acetyl leukotriene E4 was without effect and leukotriene B4 induced slight increases [6].
  • Urinary LTE4, a stable urinary end-product of LTC4 and LTD4, was measured, by means of high-performance liquid chromatography and radioimmunoassay [3].
  • Mean urinary LTE4 was higher in the asthmatic patients (78.3 [46.5-131.8] ng/mmol creatinine) than in normal subjects (p less than 0.01), although there was substantial overlap into the normal range [3].

Chemical compound and disease context of leukotriene E4


Biological context of leukotriene E4

  • All peptidyl LTs (LTC4, LTD4, and LTE4) inhibited B-1 F cell growth in a dose-dependent manner and exhibited maximum inhibition of DNA synthesis (60-80%) compared with that of untreated cells in a range of 10(-9) to 10(-8) M [12].
  • There is little conversion to LTC4 to LTE4 in purified preparations of basophils, but conversion to LTE4 does occur if cell densities are high during incubation [13].
  • LTE4 causes very long-lasting bronchoconstriction [14].
  • Inhalation challenges with either synthetic LTC4 or LTE4 were performed after prior inhalation of aerosolized SK&F 104353 or placebo in a double-blind, randomized fashion [15].
  • METHODS: A group of eight patients with asthma shown to have adverse reactions to aspirin documented by a 15% or greater decrease in forced expiratory volume in 1 second, accompanied by an elevation in urinary leukotriene E4 after ingestion of aspirin, received aspirin or placebo in a study with a crossover design [16].

Anatomical context of leukotriene E4

  • Experiments in which the SV was pretreated with L-NG-monomethyl-L-arginine (L-NMMA; 10(-4) mol/L) or indomethacin (10(-5) mol/L) or was denuded of endothelium had no significant effect on the Emax values for LTE4 [17].
  • The mutant mice retain partial ability to convert LTD4 to LTE4, ranging from 80-90% of the wild-type values in small intestine and liver to 16% in kidney and 40% in lung, heart, and pancreas [18].
  • Synthetic LTB4, LTC4, LTD4, and LTE4 were administered over 1-min periods to the isolated, perfused rat pancreas in the presence of 5.6 mM glucose [19].
  • Metabolism of leukotriene E4 in isolated rat hepatocytes. Identification of beta-oxidation products of sulfidopeptide leukotrienes [20].
  • The data that support this conclusion are: 1) LTE4 completely displaced [3H]LTD4 from its receptors in U-937 cell membranes [21].

Associations of leukotriene E4 with other chemical compounds


Gene context of leukotriene E4


Analytical, diagnostic and therapeutic context of leukotriene E4


  1. Cyclooxygenase blockade elevates leukotriene E4 production during acute anaphylaxis in sheep. Robinson, D.R., Skoskiewicz, M., Bloch, K.J., Castorena, G., Hayes, E., Lowenstein, E., Melvin, C., Michelassi, F., Zapol, W.M. J. Exp. Med. (1986) [Pubmed]
  2. Leukotrienes in the pathophysiology of kwashiorkor. Mayatepek, E., Becker, K., Gana, L., Hoffmann, G.F., Leichsenring, M. Lancet (1993) [Pubmed]
  3. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Taylor, G.W., Taylor, I., Black, P., Maltby, N.H., Turner, N., Fuller, R.W., Dollery, C.T. Lancet (1989) [Pubmed]
  4. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Carry, M., Korley, V., Willerson, J.T., Weigelt, L., Ford-Hutchinson, A.W., Tagari, P. Circulation (1992) [Pubmed]
  5. Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders. Mayatepek, E., Lehmann, W.D., Fauler, J., Tsikas, D., Frölich, J.C., Schutgens, R.B., Wanders, R.J., Keppler, D. J. Clin. Invest. (1993) [Pubmed]
  6. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Wallace, J.L., McKnight, G.W., Keenan, C.M., Byles, N.I., MacNaughton, W.K. Gastroenterology (1990) [Pubmed]
  7. Leukotriene D4 and E4 induce transmembrane signaling in human epithelial cells. Single cell analysis reveals diverse pathways at the G-protein level for the influx and the intracellular mobilization of Ca2+. Sjölander, A., Grönroos, E., Hammarström, S., Andersson, T. J. Biol. Chem. (1990) [Pubmed]
  8. Prostaglandins, thromboxanes, and leukotrienes in inflammation. Malmsten, C.L. Am. J. Med. (1986) [Pubmed]
  9. Urinary leukotriene E4 after exercise challenge in children with asthma. Kikawa, Y., Miyanomae, T., Inoue, Y., Saito, M., Nakai, A., Shigematsu, Y., Hosoi, S., Sudo, M. J. Allergy Clin. Immunol. (1992) [Pubmed]
  10. Endogenous arachidonic acid metabolism by calcium ionophore A23187-stimulated lamb lungs: effect of hypoxia. Ibe, B.O., Isenberg, W.B., Raj, J.U. Am. J. Respir. Cell Mol. Biol. (1991) [Pubmed]
  11. Increased production of cysteinyl leukotrienes in hepatorenal syndrome. Moore, K.P., Taylor, G.W., Maltby, N.H., Siegers, D., Fuller, R.W., Dollery, C.T., Williams, R. J. Hepatol. (1990) [Pubmed]
  12. Inhibition of murine transformed Leydig cell proliferation by leukotrienes in serum-free culture. Nishii, K., Nishizawa, Y., Nishizawa, Y., Matsumoto, K., Sato, B. Cancer Res. (1991) [Pubmed]
  13. Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. MacGlashan, D.W., Peters, S.P., Warner, J., Lichtenstein, L.M. J. Immunol. (1986) [Pubmed]
  14. The evolution and future horizons of research on the metabolism of arachidonic acid by 5-lipoxygenase. Piper, P.J. J. Allergy Clin. Immunol. (1984) [Pubmed]
  15. The effect of inhalation of the leukotriene receptor antagonist, SK&F 104353, on leukotriene C4- and leukotriene E4-induced bronchoconstriction in subjects with asthma. Christie, P.E., Spur, B.W., Lee, T.H. J. Allergy Clin. Immunol. (1991) [Pubmed]
  16. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. Fischer, A.R., Rosenberg, M.A., Lilly, C.M., Callery, J.C., Rubin, P., Cohn, J., White, M.V., Igarashi, Y., Kaliner, M.A., Drazen, J.M. J. Allergy Clin. Immunol. (1994) [Pubmed]
  17. Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery. Implications for graft performance. Allen, S.P., Chester, A.H., Dashwood, M.R., Tadjkarimi, S., Piper, P.J., Yacoub, M.H. Circulation (1994) [Pubmed]
  18. Leukotriene D4 and cystinyl-bis-glycine metabolism in membrane-bound dipeptidase-deficient mice. Habib, G.M., Shi, Z.Z., Cuevas, A.A., Guo, Q., Matzuk, M.M., Lieberman, M.W. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  19. Leukotrienes stimulate insulin release from the rat pancreas. Pek, S.B., Walsh, M.F. Proc. Natl. Acad. Sci. U.S.A. (1984) [Pubmed]
  20. Metabolism of leukotriene E4 in isolated rat hepatocytes. Identification of beta-oxidation products of sulfidopeptide leukotrienes. Stene, D.O., Murphy, R.C. J. Biol. Chem. (1988) [Pubmed]
  21. Mechanisms of leukotriene E4 partial agonist activity at leukotriene D4 receptors in differentiated U-937 cells. Saussy, D.L., Sarau, H.M., Foley, J.J., Mong, S., Crooke, S.T. J. Biol. Chem. (1989) [Pubmed]
  22. Metabolism of cysteinyl leukotrienes in the perfused rat liver: the influence of endotoxin pretreatment and the cellular hydration state. Wettstein, M., Noé, B., Häussinger, D. Hepatology (1995) [Pubmed]
  23. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. Kowal-Bielecka, O., Distler, O., Neidhart, M., Künzler, P., Rethage, J., Nawrath, M., Carossino, A., Pap, T., Müller-Ladner, U., Michel, B.A., Sierakowski, S., Matucci-Cerinic, M., Gay, R.E., Gay, S. Arthritis Rheum. (2001) [Pubmed]
  24. Effects of synthetic peptido-leukotrienes on bone resorption in vitro. Garcia, C., Qiao, M., Chen, D., Kirchen, M., Gallwitz, W., Mundy, G.R., Bonewald, L.F. J. Bone Miner. Res. (1996) [Pubmed]
  25. Urinary leukotriene E4 levels during early and late asthmatic responses. Manning, P.J., Rokach, J., Malo, J.L., Ethier, D., Cartier, A., Girard, Y., Charleson, S., O'Byrne, P.M. J. Allergy Clin. Immunol. (1990) [Pubmed]
  26. Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. Szczeklik, A., Dworski, R., Mastalerz, L., Prokop, A., Sheller, J.R., Nizankowska, E., Cmiel, A., Oates, J.A. Am. J. Respir. Crit. Care Med. (1998) [Pubmed]
  27. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. Kawagishi, Y., Mita, H., Taniguchi, M., Maruyama, M., Oosaki, R., Higashi, N., Kashii, T., Kobayashi, M., Akiyama, K. J. Allergy Clin. Immunol. (2002) [Pubmed]
  28. Neuropeptides and leukotriene biosynthesis: the effect of calcitonin, peptide histidine valine-42, helodermin, neuropeptide Y and galanin. Di Marzo, V., Tippins, J.R., Galadari, S.H., Morris, H.R. Neuropeptides (1988) [Pubmed]
  29. Evaluation and interference of serum and skin lesion levels of leukotrienes in patients with eczema. Hua, Z., Fei, H., Mingming, X. Prostaglandins Leukot. Essent. Fatty Acids (2006) [Pubmed]
  30. Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle. Jonsson, E.W. Acta physiologica Scandinavica. Supplementum. (1998) [Pubmed]
  31. Noninvasive assessment of hepatobiliary and renal elimination of cysteinyl leukotrienes by positron emission tomography. Guhlmann, A., Krauss, K., Oberdorfer, F., Siegel, T., Scheuber, P.H., Müller, J., Csuk-Glänzer, B., Ziegler, S., Ostertag, H., Keppler, D. Hepatology (1995) [Pubmed]
  32. Enhanced synthesis of cysteinyl leukotrienes in juvenile rheumatoid arthritis. Fauler, J., Thon, A., Tsikas, D., von der Hardt, H., Frölich, J.C. Arthritis Rheum. (1994) [Pubmed]
  33. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Joris, I., Majno, G., Corey, E.J., Lewis, R.A. Am. J. Pathol. (1987) [Pubmed]
  34. Leukotriene E4 elimination and metabolism in normal human subjects. Sala, A., Voelkel, N., Maclouf, J., Murphy, R.C. J. Biol. Chem. (1990) [Pubmed]
  35. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. Kopp, M.V., Brauburger, J., Riedinger, F., Beischer, D., Ihorst, G., Kamin, W., Zielen, S., Bez, n.u.l.l., Friedrichs, F., Von Berg, A., Gerhold, K., Hamelmann, E., Hultsch, n.u.l.l., Kuehr, J. J. Allergy Clin. Immunol. (2002) [Pubmed]
WikiGenes - Universities